 | Up a level |
Journal Article
Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M., Borchmann, P. and Engert, A. (2016). OSTEONECROSIS AFTER TREATMENT FOR HODGKIN LYMPHOMA: THE GERMAN HODGKIN STUDY GROUP EXPERIENCE. Haematologica, 101. S. 62 - 63. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Borchmann, S., Mueller, H., Haverkamp, H., Baues, C., Markova, J., Huettmann, A., Glunz, A., Fuchs, M. and Engert, A. (2016). OSTEONECROSIS AS A TREATMENT COMPLICATION IN HODGKIN LYMPHOMA PATIENTS: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG). Haematologica, 101. S. 5 - 7. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eich, H. T., Kriz, J., Reinartz, G., Kobe, C., Kuhnert, G., Haverkamp, U., Haverkamp, H., Hegerfeld, K., Baues, C. and Engert, A. (2013). Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG). Int. J. Radiat. Oncol. Biol. Phys., 87 (2). S. S5 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Kobe, C., Dietlein, M., Borchmann, P., Engert, A., Kuhnert, G., Fuchs, M., Haverkamp, H., Eich, H. T., Kriz, J. and Diehl, V. (2011). PET-Response Adapted Therapy in Hodgkin Lymphoma. Eur. J. Cancer, 47. S. S16 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049
Kobe, C., Kuhnert, G., Haverkamp, H., Fuchs, M., Kahraman, D., Eich, H. -T., Kriz, J., Baues, C., Nast-Kolb, B., Broeckelmann, P. J., Borchmann, P., Drzezga, A., Engert, A. and Dietlein, M. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin, 54 (6). S. 241 - 247. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407
Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262
von Tresckow, B., Kreissl, S., Haverkamp, H., Sasse, S., Diehl, V., Engert, A. and Borchmann, P. (2016). BEACOPP-ESCALATED FOLLOWED BY RADIOTHERAPY OF INITIAL BULK OR RESIDUAL DISEASE IN ADVANCED-STAGE HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE GHSG HD9 AND HD12 TRIALS. Haematologica, 101. S. 18 - 19. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078